SPI Pharma promises ‘fewer failures and higher yield’ with Mannogem XL

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Forgem)
(Image: Getty/Forgem)

Related tags: SPI Pharma, Mannogem XL, mannitol

SPI Pharma has launched Mannogem XL mannitol for the production of various forms of tablets, which the firm says enhances productivity compared to compendial mannitol.

Headquartered in Delaware, US, the company will showcase its Mannogem XL mannitol product at the AAPS PharmSci 360 event in Washington DC.

The newly released product delivers a formulation of mannitol that provides improved compression and disintegration properties.

Mannitol is used within pharmaceutical products as a sweetening agent, tablet and capsule diluent, and as an excipient for chewable tablets. The formulation of Mannogem XL means it can be used in the production of orally dissolving, fast melt and chewable tablets.

A spokesperson for SPI Pharma explained that Mannogem XL will create tablets with 25% greater tablet hardness and 38% quicker disintegration per tablet hardness, compared to compendial mannitol.

The spokesperson further explained: “It is a multifunctional, compendial grade of direct compression, spray dried mannitol that provides better binding and quick disintegration. XL delivers superior compactibility, simplified formulations, and can speed development at lower costs because it goes beyond acting as a standard diluent (filler) and performs as a binder with excellent disintegration.”

Companies using the product should also see productivity improvements, through development to manufacture, due to its tight particle size range, which should see greater dosage form consistency, we were told.

According to the spokesperson, manufacturers could see “fewer failures and create higher yields and tabletting rates through advanced process control and design”.

In regards to its pipeline of products to come, the spokesperson informed us that the company is initiating a new innovation strategy, of which Mannogem XL is the first product.

Earlier this year​, SPI Pharma signed an agreement with Noramco to provide “ready-to-implement” ​formulation packages for clients. The deal would see SPI Pharma provide the excipients and co-processed drug delivery platforms and Noramco provide the active pharmaceuticals ingredients (APIs).

Related news

Show more

Related products

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us

Products

View more

Webinars